Repeated Stereotactic Radiotherapy for Local Brain Metastases Failure or Distant Brain Recurrent: A Retrospective Study of 184 Patients.

ABSTRACT:

Background

The main advantages of stereotactic radiotherapy (SRT) are to delay whole-brain radiotherapy (WBRT) and to deliver ablative doses. Despite this efficacy, the risk of distant brain metastases (BM) one year after SRT ranges from 26% to 77% and 20 to 40% of patients required salvage treatment. The role and consequences of reirradiation remain unclear, particularly in terms of survival. The objective was to study overall survival (OS) and neurological death-free survival (NDFS) and to specify the prognostic factors of long-term survival.

Methods

we retrospectively reviewed the data of patients treated between 2010 and 2020 with at least two courses of SRT without previous WBRT.

Results

In total, 184 patients were treated for 915 BMs with two-to-six SRT sessions

SUBMITTER: Kuntz L 

PROVIDER: S-EPMC10605441 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature